10:30 AM EDT, 08/28/2024 (MT Newswires) -- Immix Biopharma ( IMMX ) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.

The newly added locations including Cleveland Clinic, UC Davis, and Sutter Health, feature some of the leading AL amyloidosis programs globally, broadening patient access to CAR-T NXC-201 across the US.

The Nexicart-2 trial aims to assess the safety and effectiveness of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients with sufficient cardiac function who have not previously received BCMA-targeted therapy, the company said.

Shares of Immix Biopharma ( IMMX ) were up nearly 10% in recent trading.

Price: 2.40, Change: +0.22, Percent Change: +9.86